Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer.
Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer.
复制标题
DOI：
--
复制
发表时间：
1995-09
期刊：
影响因子：
11.2
通讯作者：
Masayuki Miyake;K. Nakano;Yoshiaki Ieki;Masashi Adachi;Cheng‐long Huang;Shin-ichi Itoi;Takashi Koh;T. Taki
中科院分区：
文献类型：
--
作者：
Masayuki Miyake;K. Nakano;Yoshiaki Ieki;Masashi Adachi;Cheng‐long Huang;Shin-ichi Itoi;Takashi Koh;T. Taki
在我们之前的研究中，我们表明运动相关蛋白1（MRP-1）是mAb M31-15识别的糖蛋白，并且MRP-1的序列与WBC分化抗原CD9的序列相同。将 MRP-1/CD9 cDNA 转染到培养的非造血细胞中可抑制细胞运动。抑制的程度与MRP-1/CD9表达水平直接相关。此外，MRP-1/CD9转染的黑色素瘤BL6细胞的转移潜力低于对照BL6细胞。为了确定这些实验结果是否与实际的人类肿瘤相关，我们研究了 143 例乳腺癌浸润性导管癌中的 MRP-1/CD9 表达。在 97 例 MRP-1/CD9 阳性肿瘤患者中，只有 36 例（37.1%）有淋巴结受累。相比之下，39 名肿瘤 MRP-1/CD9 免疫反应性降低的患者中，有 21 名 (53.8%) 患者存在淋巴结转移，而 7 名原发癌未被抗 MRP-1/CD9 MAb 染色的患者中，有 5 名存在淋巴结转移。 62个原发肿瘤及其各自转移淋巴结的蛋白表达比较显示，在近50%的病例中，后者的MRP-1/CD9水平低于前者。此外，基于逆转录酶-PCR的分析显示，32名患者中有17名的转移淋巴结中MRP-1/CD9基因表达显着低于原发性浸润性导管癌。在任何研究的样本中均未观察到基因过度表达。我们的数据表明，MRP-1/CD9 低表达可能与某些人类肿瘤的转移潜力有关。
In our previous studies we showed that motility related protein 1 (MRP-1) is a glycoprotein recognized by mAb M31-15, and that the sequence of MRP-1 is identical to that of CD9, a WBC differentiation antigen. Transfection of MRP-1/CD9 cDNA into cultured nonhematopoietic cells suppresses cell motility. The extent of suppression is directly related to the level of MRP-1/CD9 expression. In addition, the metastatic potential of MRP-1/CD9-transfected melanoma BL6 cells is lower than that of control BL6 cells. To determine whether these experimental results are of relevance with respect to actual human tumors, we investigated MRP-1/CD9 expression in 143 invasive ductal carcinomas of the breast. Of 97 patients with MRP-1/CD9-positive tumors, only 36 (37.1%) had lymph node involvement. In contrast, 21 of 39 (53.8%) patients whose tumors had reduced MRP-1/CD9 immunoreactivity and 5 of 7 patients whose primary carcinomas were not stained by the anti-MRP-1/CD9 MAb had lymph node metastases. The comparison of protein expression by 62 primary tumors and their respective metastatic lymph nodes revealed that in almost 50% of the cases, the latter had lower MRP-1/CD9 levels than the former. Moreover, reverse transcriptase-PCR-based analysis disclosed that MRP-1/CD9 gene expression in the metastatic lymph nodes of 17 of 32 patients was strikingly lower than in the primary invasive ductal carcinomas. Gene overexpression was not observed in any of the samples studied. Our data suggest that low MRP-1/CD9 expression may be associated with the metastatic potential of certain human tumors.